Nanocubosomal based in situ gel loaded with natamycin for ocular fungal diseases: development, optimization, in-vitro, and in-vivo assessment

被引:21
|
作者
Hosny, Khaled M. [1 ,2 ]
Rizg, Waleed Y. [1 ,2 ]
Alkhalidi, Hala M. [3 ]
Abualsunun, Walaa A. [1 ]
Bakhaidar, Rana B. [1 ]
Almehmady, Alshaimaa M. [1 ]
Alghaith, Adel F. [4 ]
Alshehri, Sultan [4 ]
El Sisi, Amani M. [5 ]
机构
[1] King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, Jeddah 21441, Saudi Arabia
[2] King Abdulaziz Univ, Ctr Excellence Drug Res & Pharmaceut Ind, Jeddah, Saudi Arabia
[3] King Abdulaziz Univ, Fac Pharm, Dept Clin Pharm, Jeddah, Saudi Arabia
[4] King Saud Univ, Coll Pharm, Dept Pharmaceut, Riyadh, Saudi Arabia
[5] Beni Suef Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Bani Suwayf, Egypt
关键词
Cubosomes; cornea; in situ gel; keratitis; natamycin; permeation; phytantriol; DRUG-DELIVERY-SYSTEM; OPHTHALMIC DELIVERY; CORNEAL PENETRATION; FORMULATION; CUBOSOMES; INFECTIONS; KERATITIS; NANOPARTICLES; NANOCARRIERS; LIPOSOMES;
D O I
10.1080/10717544.2021.1965675
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Natamycin (NT) is a synthetic broad-spectrum antifungal used in eye drops. However, it has low solubility and high molecular weight, limiting its permeation, and generally causes eye discomfort or irritation when administered. Therefore, the present study aimed to develop an ophthalmic in situ gel formulation with NT-loaded cubosomes to enhance ocular permeation, improve antifungal activity, and prolong the retention time within the eye. The NT-loaded cubosome (NT-Cub) formula was first optimized using an I-optimal design utilizing phytantriol, PolyMulse, and NT as the independent formulation factors and particle size, entrapment efficiency %, and inhibition zone as responses. Phytantriol was found to increase particle size and entrapment efficiency %. Higher levels of PolyMulse slightly increased the inhibition zone whereas a decrease in particle size and EE% was observed. Increasing the NT level initially increased the entrapment efficiency % and inhibition zone. The optimized NT-Cub formulation was converted into an in situ gel system using 1.5% Carbopol 934. The optimum formula showed a pH-sensitive increase in viscosity, favoring prolonged retention in the eye. The in vitro release of NT was found to be 71 +/- 4% in simulated tear fluid. The optimum formulation enhanced the ex vivo permeation of NT by 3.3 times compared to a commercial formulation and 5.2 times compared to the NT suspension. The in vivo ocular irritation test proved that the optimum formulation is less irritating than a commercial formulation of NT. This further implies that the developed formulation produces less ocular irritation and can reduce the required frequency of administration.
引用
收藏
页码:1836 / 1848
页数:13
相关论文
共 50 条
  • [41] Development of Tizanidine HCI-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation
    Zaman, Muhammad
    Hanif, Muhammad
    Shaheryar, Zaib Ali
    PLOS ONE, 2018, 13 (03):
  • [42] Sustained ocular delivery of Dorzolamide-HCl via proniosomal gel formulation: in-vitro characterization, statistical optimization, and in-vivo pharmacodynamic evaluation in rabbits
    Fouda, Nagwa Hussein
    Abdelrehim, Randa Tag
    Hegazy, Doaa Abdelmagid
    Habib, Basant Ahmed
    DRUG DELIVERY, 2018, 25 (01) : 1340 - 1349
  • [43] Development of thermosensitive hydrogel of Amphotericin-B and Lactoferrin combination-loaded PLGA-PEG-PEI nanoparticles for potential eradication of ocular fungal infections: In-vitro, ex-vivo and in-vivo studies
    Elhabal, Sammar Fathy
    Ghaffar, Shrouk A.
    Hager, Raghda
    Elzohairy, Nahla A.
    Khalifa, Mohamed Mansour
    Mohie, Passant M.
    Gad, Rania A.
    Omar, Nasreen N.
    Elkomy, Mohammed H.
    Khasawneh, Mohammad Ahmad
    Abdelaal, Nashwa
    INTERNATIONAL JOURNAL OF PHARMACEUTICS-X, 2023, 5
  • [44] Formulation, Optimization, In-Vitro and In-Vivo Evaluation of Nateglinide-Loaded Nanostructured Lipid Carriers for Enhanced Bioavailability
    Tiwari, Shradha S.
    Dange, Yuvraj D.
    Honmane, Sandip M.
    Saralaya, Mahesh G.
    Gattani, Surendra G.
    Wadher, Shailesh J.
    Sarda, Rohit R.
    Mahaparale, Paresh R.
    BIONANOSCIENCE, 2025, 15 (01)
  • [45] Preparation, in-vitro and in-vivo evaluation of Rifampicin and Vancomycin Co-loaded transfersomal gel for the treatment of cutaneous leishmaniasis
    Salim, Muhammad Waqas
    Shabbir, Kanwal
    ud-Din, Fakhar
    Yousaf, Abid Mehmood
    Choi, Han-Gon
    Khan, Gul Majid
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2020, 60
  • [46] Development and Optimization of Cefuroxime Axetil Nanosuspension for Improved Oral Bioavailability: In-Vitro and In-Vivo Investigations
    Haragouri Mishra
    Amulyaratna Behera
    Sidhartha Sankar Kar
    Swagatika Dash
    Srikanta Moharana
    Suresh Sagadevan
    BioNanoScience, 2023, 13 : 2371 - 2384
  • [47] Development and Optimization of Cefuroxime Axetil Nanosuspension for Improved Oral Bioavailability: In-Vitro and In-Vivo Investigations
    Mishra, Haragouri
    Behera, Amulyaratna
    Kar, Sidhartha Sankar
    Dash, Swagatika
    Moharana, Srikanta
    Sagadevan, Suresh
    BIONANOSCIENCE, 2023, 13 (04) : 2371 - 2384
  • [48] Food amyloid fibrils are safe nutrition ingredients based on in-vitro and in-vivo assessment
    Dan Xu
    Jiangtao Zhou
    Wei Long Soon
    Ines Kutzli
    Adrian Molière
    Sabine Diedrich
    Milad Radiom
    Stephan Handschin
    Bing Li
    Lin Li
    Shana J. Sturla
    Collin Y. Ewald
    Raffaele Mezzenga
    Nature Communications, 14
  • [49] Food amyloid fibrils are safe nutrition ingredients based on in-vitro and in-vivo assessment
    Xu, Dan
    Zhou, Jiangtao
    Soon, Wei Long
    Kutzli, Ines
    Moliere, Adrian
    Diedrich, Sabine
    Radiom, Milad
    Handschin, Stephan
    Li, Bing
    Li, Lin
    Sturla, Shana J.
    Ewald, Collin Y.
    Mezzenga, Raffaele
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [50] PLGA-modified Syloid®-based microparticles for the ocular delivery of terconazole: in-vitro and in-vivo investigations
    Zaghloul, Nada
    Mahmoud, Azza A.
    Elkasabgy, Nermeen A.
    El Hoffy, Nada M.
    DRUG DELIVERY, 2022, 29 (01) : 2117 - 2129